Navigation Links
Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
Date:10/28/2009

BAD HOMBURG, Germany and LACHEN, Switzerland, Oct. 28 /PRNewswire/ -- Octapharma Group and Fresenius Kabi have signed a License, Development and Supply Agreement regarding the use of Fresenius Kabi's HESylation® Technology to develop a HESylated recombinant protein.

Under the agreement, Fresenius Kabi will license its proprietary HESylation® Technology to Octapharma. This technology platform is based on hydroxyethyl starch ("HES") which will be combined with a recombinant protein from Octapharma's human cell-line platform -- this combination is intended to generate a therapeutic protein with a superior product profile.

Fresenius Kabi will seek to adapt and optimize the protein modification by its HESylation® Technology and will afterwards be responsible for providing the appropriate HES derivative to Octapharma. Under the agreement, Octapharma will oversee the further development and commercialization. Fresenius Kabi will receive up-front and milestone payments, research funding and royalties on sales for licensing of the HESylation® Technology.

Octapharma's human cell-line platform

Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell lines. Over the last twelve years, Octapharma has successfully established the human HEK293F cell-line platform for the expression of a variety of recombinant therapeutic proteins on a commercial scale.

An investigational new drug application for Octapharma's human cell-line derived recombinant FVIII was filed in the U.S. in May 2008. Using a human cell-line expression system instead of e.g. hamster cell-lines is expected to result in possible advantages like improved protein functions, increased tolerability and the opportunity for reduced immunogenicity.

HESylation® Technology

HESylation® Technology is based on th
'/>"/>

SOURCE Octapharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
2. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
3. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
4. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
5. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
6. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
7. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
8. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
9. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
10. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
11. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Ill. , Dec. 19, 2014   Hospira, ... leading provider of injectable drugs and infusion technologies, today ... Morgan 33rd Annual Healthcare Conference on Wednesday, Jan. 14, ... presentation is scheduled to begin at 10:30 a.m. Pacific ... available to all interested parties through a live audiocast ...
(Date:12/19/2014)... -- Monarch America Inc. (OTCQB: CANK) ("Monarch America" or the ... this review of the Company,s recent achievements and strategic ... this past year, we achieved many of our early ... say that Monarch America is in a stronger and ... stated Eric Hagen , CEO of Monarch America ...
(Date:12/19/2014)... , Dec. 18, 2014 Somewhere between dropping ... health was forgotten. But Audicus , a next-generation ... better this new year. Hearing loss is ... aging population, though it is often unaddressed. Forty-eight million ... has a hearing aid, mainly due to price. Hearing ...
Breaking Medicine Technology:Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Audicus Will Help People Resolve to Hear Better in 2015 2
... 1, 2010 ACCESS PHARMACEUTICALS, ... a biopharmaceutical company leveraging its proprietary drug-delivery ... supportive care and diabetes, announced it has ... recently enacted Patient Protection and Affordable Care Act, cash ...
... 2010 The National Quality Forum (NQF) announces ... eight member councils.   NQF is ... the quality of American healthcare by setting national ... consensus standards for measuring and publicly reporting on ...
Cached Medicine Technology:Access Pharmaceuticals Awarded $1.5 Million in Section 48D Grants 2National Quality Forum Members Elect New Council Leaders 2
(Date:12/20/2014)... Developers of FCPX 3rd ... plugin for Final Cut Pro X entitled TranSlice Volume ... allows users to create hand drawn text animations without ... CEO of Pixel Film Studios. “TranSlice Volume 5 was ... an easy to use interface.” , TranSlice Volume 5 ...
(Date:12/20/2014)... Twin Cities DI Day is recognized as the premier ... financial professionals come together each year to hear up ... to protect their clients and to be inspired by ... of disability. , On September 23rd, 2014, financial professionals ... The 13th Annual Twin Cities DI Day where they ...
(Date:12/20/2014)... Today, Balfleet.com, one of the most ... offering 50%-70% off on its Mother of the ... mother of the bride dresses from Balfleet.com feature gorgeous ... accessible and takes pride in providing high quality dresses ... offering great discounts on our mother of the bride ...
(Date:12/19/2014)... Montrose, Colorado (PRWEB) December 20, 2014 It’s ... many, travel is something that is put to the wayside ... those who still have that travel “itch” and that burning ... Inn Montrose accommodates families on their journey to Telluride with ... trip, get visitors to and from the resort, and ensure ...
(Date:12/19/2014)... Sub Zero Ice Cream is partnering up ... Sunday the 28th from 2pm-6pm at the Expo Center on ... Sarasota, FL. , Inquiries regarding time slots and signing up, ... the donating process, Sub Zero Ice Cream & Yogurt will ... cream. , About Sub Zero Ice Cream & Yogurt ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:The 13th Annual Twin Cities DI Day Now On Video 2Health News:The 13th Annual Twin Cities DI Day Now On Video 3Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2
... Safety and Efficacy Study of Zolpidem Tartrate ... an As-Needed BasisEvaluation of Ondansetron Augmentation in ... May 21 Transcept Pharmaceuticals, Inc. (Nasdaq: ... company focused on the development and commercialization ...
... offers patients better results and quicker recovery as ... currently on the market; Now available in powerful ... Palomar Medical Technologies, Inc. (Nasdaq: PMTI ... systems for cosmetic treatments, announced today the success ...
... Inc. (MDLH. PK) ( http://www.mitcanada.ca http://www.mitinvest.ca ), ... the Joint Venture Agreement with its Chinese partners. , ... most recent trip to China having completed the negotiations and ... has also received an initial order of 120 Agro-Jet(R) for ...
... Challenging Anatomy Consistent with Superior Results from Randomized ... presented today at EuroPCR from an international, post-approval, ... Everolimus Eluting Coronary Stent System demonstrated low rates ... and major adverse cardiac events (MACE) in a ...
... finds many women use spending sprees to boost emotional well-being ... -- When dealing with financial worries, some women may actually ... shows. , The poll of 700 women found that 79 ... themselves an emotional boost. About 40 percent listed "depression" and ...
... compared to vaginal birth newborns, researchers say , , THURSDAY, ... elective, repeat cesarean section delivery are nearly twice as ... unit (NICU) than those born vaginally after the mother ... , These c-section babies are also more likely to ...
Cached Medicine News:Health News:Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association 2Health News:Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association 3Health News:Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association 4Health News:New Clinical Data Shows Significant Improvement in the Appearance of Fat Using SlimLipo(TM) Laser 2Health News:New Clinical Data Shows Significant Improvement in the Appearance of Fat Using SlimLipo(TM) Laser 3Health News:New Clinical Data Shows Significant Improvement in the Appearance of Fat Using SlimLipo(TM) Laser 4Health News:MIT is pleased to announce that it has signed the Joint Venture agreement with its Chinese partners and has received an initial order of 120 units for Animal vaccination 2Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 2Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 3Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 4Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 5Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 6Health News:Shop 'Til You Drop: You May Feel Better 2Health News:Risk to Baby Rises With Repeat C-Sections 2Health News:Risk to Baby Rises With Repeat C-Sections 3
... path that allows users to take full ... potential to combine two units offers fully ... stimulating coil. The ability to change pulse ... level of each Magstim 200 allows for ...
... is a surgical approach to glaucoma management ... application. The ciliary body (which produces aqueous ... the anterior or posterior segment, through the ... are easily and accurately identified utilizing endoscopy. ...
... surgical approach to glaucoma management that employs ... ciliary body (which produces aqueous humour) is ... or posterior segment, through the endoscope in ... and accurately identified utilizing endoscopy. This allows ...
... of German Craftsmanship have produced ... the world. Ocutek® now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
Medicine Products: